BrainStorm Cell Therapeutics Inc. (BCLI) stock

BCLIOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 0/30

$0.77−0.01 (-1.17%)

Close on Oct 19, 2026Market cap $8.50MP/E –Yield –

BrainStorm Cell Therapeutics gross profit

Gross profit is revenue minus the direct cost of the goods and services sold.

BrainStorm Cell Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

See a number that looks wrong?